Research
Hormonal
Extending the dose-escalation period or temporarily suspending dose increases when gastrointestinal adverse events occur improves tolerability and treatment persistence without compromising long-term efficacy.
If you feel sick after a dose increase, don't rush to the next one. Stay at the current dose for a few extra weeks or pause until you feel better. This helps your body adjust and keeps you on the medication longer.
GoodSupportsHIGH confidence
If GI AEs appear during the dose-escalating phase, HCPs could modify the planned schedule by implementing one or several of the following points: Extend the dose escalation phase duration (2–4 more weeks with the previous dose or temporary suspension).
Why this rating
Expert consensus based on clinical trial data and real-world experience.
Source
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Juan José Gorgojo Martínez et al. · Journal of Clinical Medicine · 2022
DOI 10.3390/jcm12010145
clinical_guidelineCited 277×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Adhering to specific dietary modifications (smaller portions, low-fat, bland foods) and slow eating habits significantly reduces the frequency and severity of gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) in patients initiating GLP-1 receptor agonist therapy.Good
- Pharmacological management of persistent nausea with domperidone (preferred over metoclopramide) or other anti-emetics/prokinetics is an effective strategy for managing GLP-1 RA-induced nausea when dietary and titration strategies fail.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →